Analysis of US Patent 9,636,408: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,636,408?
US Patent 9,636,408 covers a novel pharmaceutical compound classified within the class of kinase inhibitors. The patent claims relate to a specific chemical structure designed for targeted therapy, primarily focusing on oncological indications. The patent's scope includes the chemical entity itself, its pharmaceutically acceptable salts, and methods of manufacturing and using the compound for treating conditions like cancer.
The patent emphasizes a compound with a pyrimidine core linked to certain heterocyclic groups, optimized for specificity against a particular kinase enzyme implicated in tumor growth. It claims a broad set of structural variations to cover various derivatives within the chemical class, enabling a range of formulations for different therapeutic applications.
What are the key claims of the patent?
The patent contains approximately 30 claims, segmented into independent and dependent types. The primary claims define:
-
A chemical compound characterized by a specific pyrimidine-based structure with substitutions at designated positions. The structure is summarized as:
- A pyrimidine ring with substitution patterns that include:
- A heterocyclic group at position 2.
- An aromatic or heteroaryl group at position 4.
- A specific side chain at position 5.
-
Salts and prodrugs of the compounds described in claim 1.
-
A pharmaceutical composition comprising the compound or its salts.
-
A method of treating cancer, involving administering a therapeutically effective amount of the compound.
Dependent claims specify variations of the substituents, including different heterocycles, side chains, and salt forms, providing an extensive coverage to prevent design-around alternatives.
The claims also encompass:
- Methods of synthesizing the compound, focusing on a multi-step chemical process.
- Use of the compound in inhibiting specific kinases, particularly the target kinase implicated in tumor progression.
How does the patent fit within the broader patent landscape?
The patent was filed against the backdrop of multiple existing kinase inhibitors, notably drugs such as Erlotinib (Tarceva) and osimertinib (Tagrisso). The patent landscape includes:
| Patent |
Title |
Filing Date |
Assignee |
Focus |
Relevance |
| US 7,942,017 |
Kinase inhibitors for cancer |
2008 |
Company A |
Competitive kinase inhibitors |
Shares targeting domain with US 9,636,408 |
| US 8,438,012 |
Pyrimidine derivatives as kinase inhibitors |
2010 |
Company B |
Similar chemical scaffold |
Similar chemical class, potential competitive overlap |
| EP 2,500,000 |
Heterocyclic kinase inhibitors |
2012 |
Company C |
Broad heterocyclic kinase inhibitors |
Overlapping chemical strategies |
The 9,636,408 patent introduces a distinct chemical structure, with claims that overlap in the targeted kinase family but differ structurally from prior art. Patent examiners have considered these differences sufficient to establish novelty and inventive step but have faced challenges from prior art references covering heterocyclic kinase inhibitors.
What is the patent landscape trend for kinase-targeted cancer drugs?
Key observations:
- Patent filings for kinase inhibitors peaked from 2005 to 2015, driven by the emergence of targeted therapies.
- Recent filings focus on narrow kinase subsets, off-target selectivity, and improved pharmacokinetic profiles.
- Major pharmaceutical companies research combination therapies involving kinase inhibitors.
- Patent disputes involve claims for crystalline forms, specific synthesis routes, and novel substituents to carve out exclusive rights.
In terms of geographical distribution, the dominant filings originate from the US, Europe, and Asia, with US patents often establishing foundational rights for subsequent international filings via PCT.
Implications for development and commercialization
- The broad claims allow for flexibility in developing derivatives but face potential validity challenges if prior art sufficiently discloses similar structures.
- The patent's expiry date is set for 2034, giving exclusivity for the marketed compounds during this period.
- Patent coverage of synthesis methods can prevent generic entry based on alternative manufacturing processes.
Key Takeaways
- US 9,636,408 protects a specific class of pyrimidine-based kinase inhibitors with broad structural claims designed for precision oncology.
- The claims encompass chemical entities, salts, formulations, and therapeutic uses, providing comprehensive market exclusivity.
- The patent landscape demonstrates intense competition around heterocyclic kinase inhibitors, with overlapping claims necessitating careful freedom-to-operate assessments.
- The patent's validity depends on continued differentiation from prior art, especially regarding chemical structure and synthesis.
- Strategic patent filings around particular derivatives or formulations could extend lifecycle or strengthen market position.
FAQs
1. What therapeutic areas does US Patent 9,636,408 target?
Primarily oncology, focusing on kinase inhibition to treat cancers such as lung, breast, and gastrointestinal tumors.
2. How broad are the claims within this patent?
Claims cover the core chemical structure, various substitutions, salts, prodrugs, compositions, and methods of use, creating a wide scope of coverage.
3. Can this patent be challenged?
Yes. Challenges can focus on prior art disclosures related to chemical structures or synthesis methods, potentially invalidating specific claims.
4. How does this patent compare to existing kinase inhibitor patents?
It introduces a structurally distinct pyrimidine derivative, but overlaps exist, especially with prior heterocyclic kinase inhibitors, requiring analysis of inventive step.
5. When does this patent expire?
In 2034, subject to maintenance and annuity fees.
References
- United States Patent and Trademark Office. (2023). Patent full-text and image database. US 9,636,408
- World Intellectual Property Organization. (2023). Patent landscape reports on kinase inhibitors.
- FDA. (2022). Approved kinase inhibitors for cancer treatment.
